2211-3207

International Journal for Parasitology Drugs and Drug Resistance

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 657 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact657 DOIs
2

Attach ORCID iDs across 263 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact263 DOIs
3

Deposit reference lists for 13 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact13 DOIs

DOIs for this ISSN

Showing the top 5 of 657 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Drug repurposing and human parasitic protozoan diseases (10.1016/j.ijpddr.2014.02.002)
Abstract ORCID
123.34 292
2 Moxidectin and the avermectins: Consanguinity but not identi… (10.1016/j.ijpddr.2012.04.001)
Abstract ORCID
118.37 232
3 Is anthelmintic resistance a concern for the control of huma… (10.1016/j.ijpddr.2011.09.002)
Abstract ORCID
116.11 209
4 Visceral leishmaniasis treatment: What do we have, what do w… (10.1016/j.ijpddr.2012.01.003)
Abstract ORCID
114.72 196
5 Drug resistance in liver flukes (10.1016/j.ijpddr.2019.11.003)
Abstract ORCID
111.90 172
6 Repurposing drugs for the treatment and control of helminth… (10.1016/j.ijpddr.2014.07.002)
Abstract ORCID
110.34 160
7 Recent advances in candidate-gene and whole-genome approache… (10.1016/j.ijpddr.2014.07.007)
Abstract ORCID
108.22 145
8 P-glycoproteins and other multidrug resistance transporters… (10.1016/j.ijpddr.2011.10.001)
Abstract ORCID
108.07 144
9 Anthelmintic resistance in equine nematodes (10.1016/j.ijpddr.2014.10.003)
Abstract ORCID
108.07 144
10 Anthelmintic resistance to ivermectin and moxidectin in gast… (10.1016/j.ijpddr.2015.08.001)
Abstract ORCID
106.36 133
11 Perspectives on the utility of moxidectin for the control of… (10.1016/j.ijpddr.2019.06.002)
Abstract ORCID
104.50 122
12 Vaccination of chickens against coccidiosis ameliorates drug… (10.1016/j.ijpddr.2014.10.002)
Abstract ORCID
104.32 121
13 Aminoacyl-tRNA synthetases as drug targets in eukaryotic par… (10.1016/j.ijpddr.2013.10.001)
Abstract ORCID
103.78 118
14 Current trends in the pharmacological management of Chagas d… (10.1016/j.ijpddr.2019.11.004)
Abstract ORCID
103.59 117
15 Synergistic inhibition of Haemonchus contortus exsheathment… (10.1016/j.ijpddr.2015.06.001)
Abstract ORCID
102.65 112
16 Refugia and anthelmintic resistance: Concepts and challenges (10.1016/j.ijpddr.2019.05.001)
Abstract ORCID
102.65 112
17 The malaria parasite cation ATPase PfATP4 and its role in th… (10.1016/j.ijpddr.2015.07.001)
Abstract ORCID
101.87 108
18 Artemisinin-based combination therapy (ACT) and drug resista… (10.1016/j.ijpddr.2020.11.006)
Abstract ORCID
98.19 91
19 Ion channels and receptor as targets for the control of para… (10.1016/j.ijpddr.2011.09.003)
Abstract ORCID
97.22 87
20 Persistent detection of Plasmodium falciparum, P. malariae,… (10.1016/j.ijpddr.2013.01.001)
Abstract ORCID
97.22 87
21 Application of a resazurin-based high-throughput screening a… (10.1016/j.ijpddr.2012.02.002)
Abstract ORCID
96.47 84
22 Confirmation of Fasciola hepatica resistant to triclabendazo… (10.1016/j.ijpddr.2013.11.005)
Abstract ORCID
96.21 83
23 Recent developments in sterol 14-demethylase inhibitors for… (10.1016/j.ijpddr.2011.12.002)
Abstract ORCID
95.42 80
24 Utilization of computer processed high definition video imag… (10.1016/j.ijpddr.2014.08.003)
Abstract ORCID
95.42 80
25 Challenges and opportunities for the adoption of molecular d… (10.1016/j.ijpddr.2020.11.005)
Abstract ORCID
93.75 74
26 Artemisinin resistance in Plasmodium falciparum: A process l… (10.1016/j.ijpddr.2012.01.001)
Abstract ORCID
93.17 72
27 Quantitative proteomic analysis of amphotericin B resistance… (10.1016/j.ijpddr.2014.05.002)
Abstract ORCID
92.87 71
28 Comparative tissue pharmacokinetics and efficacy of moxidect… (10.1016/j.ijpddr.2012.11.001)
Abstract ORCID
91.63 67
29 The proteasome of malaria parasites: A multi-stage drug targ… (10.1016/j.ijpddr.2011.12.001)
Abstract ORCID
91.30 66
30 Automated, high-throughput, motility analysis in Caenorhabdi… (10.1016/j.ijpddr.2014.10.004)
Abstract ORCID
91.30 66
31 Route map for the discovery and pre-clinical development of… (10.1016/j.ijpddr.2019.06.003)
Abstract ORCID
90.98 65
32 Molecular determinants of sulfadoxine-pyrimethamine resistan… (10.1016/j.ijpddr.2016.08.004)
Abstract ORCID
90.31 63
33 microRNAs of parasitic helminths – Identification, character… (10.1016/j.ijpddr.2014.03.001)
Abstract ORCID
89.97 62
34 Focused review: The role of drug combinations for the contro… (10.1016/j.ijpddr.2022.01.001)
Abstract ORCID
89.62 61
35 Functional expression of TcoAT1 reveals it to be a P1-type n… (10.1016/j.ijpddr.2013.01.004)
Abstract ORCID
88.54 58
36 Repurposing of approved drugs from the human pharmacopoeia t… (10.1016/j.ijpddr.2014.09.001)
Abstract ORCID
88.54 58
37 Untargeted metabolomic analysis of miltefosine action in Lei… (10.1016/j.ijpddr.2013.11.002)
Abstract ORCID
87.02 54
38 Identification of plumbagin and sanguinarine as effective ch… (10.1016/j.ijpddr.2012.12.001)
Abstract ORCID
86.62 53
39 A comparative study of the effects of four treatment regimes… (10.1016/j.ijpddr.2013.02.001)
Abstract ORCID
86.62 53
40 Novel benzoxaborole, nitroimidazole and aminopyrazoles with… (10.1016/j.ijpddr.2019.02.002)
Abstract ORCID
85.80 51
41 Nitroimidazole drugs vary in their mode of action in the hum… (10.1016/j.ijpddr.2012.04.002)
Abstract ORCID
85.38 50
42 First report of closantel treatment failure against Fasciola… (10.1016/j.ijpddr.2015.07.003)
Abstract ORCID
85.38 50
43 Similarities and differences in the biotransformation and tr… (10.1016/j.ijpddr.2019.09.001)
Abstract ORCID
85.38 50
44 Distribution patterns of three sodium channel mutations asso… (10.1016/j.ijpddr.2012.08.001)
Abstract ORCID
84.95 49
45 In vitro and in vivo assessment of the effect of antiprotozo… (10.1016/j.ijpddr.2015.04.001)
Abstract ORCID
84.95 49
46 The rule of five should not impede anti-parasitic drug devel… (10.1016/j.ijpddr.2017.05.003)
Abstract ORCID
84.51 48
47 Repurposing of an old drug: In vitro and in vivo efficacies… (10.1016/j.ijpddr.2018.10.011)
Abstract ORCID
84.51 48
48 Evidence for reversion towards anthelmintic susceptibility i… (10.1016/j.ijpddr.2015.01.001)
Abstract ORCID
84.06 47
49 Effects of in vitro exposure to ivermectin and levamisole on… (10.1016/j.ijpddr.2016.03.001)
Abstract ORCID
84.06 47
50 CYP51 structures and structure-based development of novel, p… (10.1016/j.ijpddr.2012.06.001)
Abstract ORCID
83.60 46